Clinical Trial Update: Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating the PfSPZ vaccine for safety, tolerability, and efficacy in healthy children and infants aged 5 months to 9 years living …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• PfSPZ Vaccine (Plasmodium falciparum sporozoite vaccine)

Snippet

Sponsor: Sanaria Inc. | Conditions: Malaria | Phase 1, Phase 2 | Status: COMPLETED